Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITI-1284 PET Study in Healthy Subjects
NCT06299410Phase 1Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Apr 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of deulumateperone (6 cohorts), sponsored by Intra-Cellular Therapies. Primary endpoint: Percentage Receptor Occupancy at Day 1. Started Apr 2024; status: completed.
02
Drugs
deulumateperone
Beyond the preview
Go deeper on NCT06299410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06299410.